The earnings season is off to a rough start for drugmakers.
Drug and health-care stocks were some of the worst performers in the U.S. on Tuesday as investors began to worry that pressure on pharmaceutical prices will once again hurt results.
Pharmaceutical and biotech stocks were among the biggest decliners in the Standard & Poor’s 500 Index, with medical distributors being the most hit. On the Nasdaq Composite Index, the health-care subgroup had the worst day, as well.
Continue Reading on Bloomberg